On November 4, DUALITYBIO-B rose 5.03% intraday in Regular Trading, trading at HK$106.8, with turnover of HK$72.44 million.
The latest publicly available catalyst is continued insider support: the board chairman bought 30,000 shares on November 2 at an average price of HK$103.423 per share, involving about HK$3.10 million, lifting his stake to about 16.11 million shares, or 17.53%.
That followed the company’s November 3 disclosure that it repurchased 15,000 shares on-market at HK$99.40 to HK$101.20 per share for about HK$1.51 million. The company had also disclosed earlier buybacks, including 10,000 shares on November 2 for about HK$0.99 million, while management had previously announced a voluntary lock-up commitment and a plan for further chairman share purchases. Together, these updates indicate sustained management confidence after recent clinical-data-related volatility.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments